Patient-Reported Outcomes and Impact of Type 2 Diabetes: A Cross-Sectional Study in the Kingdom of Saudi Arabia.
Kingdom of Saudi Arabia
health-related quality of life
impacts
patient-reported outcomes
preferences
type 2 diabetes
Journal
Patient preference and adherence
ISSN: 1177-889X
Titre abrégé: Patient Prefer Adherence
Pays: New Zealand
ID NLM: 101475748
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
06
2020
accepted:
06
10
2020
entrez:
18
11
2020
pubmed:
19
11
2020
medline:
19
11
2020
Statut:
epublish
Résumé
The Kingdom of Saudi Arabia (KSA) has the second highest prevalence of type 2 diabetes mellitus (T2DM) in the Middle East. There is a paucity of research on the experiences and treatment preferences of patients with T2DM in KSA. This study explored Saudi patients' health-related quality of life, eating habits, experiences during Ramadan, and preference between two glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment devices. A cross-sectional, observational study was conducted in three cities in KSA. Participants completed sociodemographic and clinical forms, EQ-5D-5L, Impact of Weight on Self-Perceptions, and a diabetes treatment survey. Participants also viewed instructional videos on GLP-1 RA injection devices and indicated their device preference. Of the 310 participants, 53% were male. The mean age was 43 years (range: 30.0-75.0), duration since diabetes diagnosis was 6.3 years (range: 0.2-27.1), the most commonly reported last HbA1c level was between ≥7.1% and 8% (45%). The mean EQ-5D-5L index score was 0.90, with some participants reporting problems with pain/discomfort (34.5%) and usual activities (33.2%). Patients reported a low-to-moderate impact of weight on self-perception. In preparation for Ramadan, participants sought physician advice on diabetes management (37%) and/or increased checks of their blood glucose (37%). After watching the videos, 89% (n=277) of participants indicated a device preference, with significantly more preferring the dulaglutide device (n=186, 67%) over the semaglutide device (n=91, 33%) (p<0.0001). This study indicates that T2DM has a significant social, emotional, and behavioral impact on the lives of patients in KSA.
Sections du résumé
BACKGROUND
BACKGROUND
The Kingdom of Saudi Arabia (KSA) has the second highest prevalence of type 2 diabetes mellitus (T2DM) in the Middle East. There is a paucity of research on the experiences and treatment preferences of patients with T2DM in KSA. This study explored Saudi patients' health-related quality of life, eating habits, experiences during Ramadan, and preference between two glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment devices.
METHODS
METHODS
A cross-sectional, observational study was conducted in three cities in KSA. Participants completed sociodemographic and clinical forms, EQ-5D-5L, Impact of Weight on Self-Perceptions, and a diabetes treatment survey. Participants also viewed instructional videos on GLP-1 RA injection devices and indicated their device preference.
RESULTS
RESULTS
Of the 310 participants, 53% were male. The mean age was 43 years (range: 30.0-75.0), duration since diabetes diagnosis was 6.3 years (range: 0.2-27.1), the most commonly reported last HbA1c level was between ≥7.1% and 8% (45%). The mean EQ-5D-5L index score was 0.90, with some participants reporting problems with pain/discomfort (34.5%) and usual activities (33.2%). Patients reported a low-to-moderate impact of weight on self-perception. In preparation for Ramadan, participants sought physician advice on diabetes management (37%) and/or increased checks of their blood glucose (37%). After watching the videos, 89% (n=277) of participants indicated a device preference, with significantly more preferring the dulaglutide device (n=186, 67%) over the semaglutide device (n=91, 33%) (p<0.0001).
CONCLUSION
CONCLUSIONS
This study indicates that T2DM has a significant social, emotional, and behavioral impact on the lives of patients in KSA.
Identifiants
pubmed: 33204074
doi: 10.2147/PPA.S265126
pii: 265126
pmc: PMC7667182
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2231-2242Informations de copyright
© 2020 Gelhorn et al.
Déclaration de conflit d'intérêts
Heather L. Gelhorn, Louis S. Matza, Jessica B. Jordan, Savita B. Anand, and Huda Shalhoub are employees of Evidera, a company that received funding from Eli Lilly for time spent conducting this research. Alena A. Strizek, Kristina S. Boye, and Ali Alhammad are employees of and own stock in Eli Lilly and Company. Dr. Aishah A. Ekhzaimy is not an employee of Eli Lilly and Company and has no conflict of interest to disclose. The authors report no other potential conflicts of interest for this work.
Références
Diabetes Metab Syndr Obes. 2018 Jan 31;11:15-21
pubmed: 29430192
Drugs R D. 2019 Jun;19(2):213-225
pubmed: 31115873
Diabetes Metab Syndr Obes. 2018 Oct 16;11:633-640
pubmed: 30410375
Value Health. 2004 Mar-Apr;7(2):204-15
pubmed: 15164810
Int J Gen Med. 2018 Jan 24;11:33-40
pubmed: 29416371
Diabetes Metab Res Rev. 1999 May-Jun;15(3):205-18
pubmed: 10441043
J Epidemiol Glob Health. 2016 Mar;6(1):29-36
pubmed: 26257035
Mycoses. 2017 Dec;60(12):800-807
pubmed: 28925059
Patient Prefer Adherence. 2019 Oct 25;13:1839-1850
pubmed: 31749610
Diabetes Technol Ther. 2015 Mar;17(3):210-4
pubmed: 25353705
BMJ Open Diabetes Res Care. 2018 May 5;6(1):e000512
pubmed: 29755756
Diabetologia. 2018 Dec;61(12):2461-2498
pubmed: 30288571
Diabetes Care. 2020 Feb;43(2):487-493
pubmed: 31857443
Adv Ther. 2018 Nov;35(11):1735-1745
pubmed: 30374807
Ann Saudi Med. 2011 Jan-Feb;31(1):19-23
pubmed: 21245594
World J Diabetes. 2017 Apr 15;8(4):120-129
pubmed: 28465788
J Med Econ. 2019 Aug;22(8):806-813
pubmed: 31010349
Health Policy. 1996 Jul;37(1):53-72
pubmed: 10158943
Qual Life Res. 2019 Apr;28(4):1053-1061
pubmed: 30470970
Value Health. 2014 Jan-Feb;17(1):70-6
pubmed: 24438719
Diabetes Res Clin Pract. 2017 Oct;132:19-26
pubmed: 28783529
Curr Med Res Opin. 2014 Nov;30(11):2329-41
pubmed: 25105306
Curr Diabetes Rev. 2016;12(4):359-368
pubmed: 26206092
J Biopharm Stat. 2017;27(5):834-844
pubmed: 27936352
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
Prim Care Diabetes. 2016 Dec;10(6):415-424
pubmed: 27297805
Diabetes Obes Metab. 2020 Mar;22(3):355-364
pubmed: 31646727
Patient Prefer Adherence. 2016 Jul 25;10:1337-48
pubmed: 27524889
Patient Prefer Adherence. 2015 Nov 09;9:1611-22
pubmed: 26635470
J Pak Med Assoc. 2016 Jun;66(6):722-5
pubmed: 27339576
BMJ Open. 2019 Jul 23;9(7):e029280
pubmed: 31340969